Biovail Signs Deals With Acadia, GSK | May 11, 2009 Issue - Vol. 87 Issue 19 | Chemical & Engineering News
Volume 87 Issue 19 | p. 17 | Concentrates
Issue Date: May 11, 2009

Biovail Signs Deals With Acadia, GSK

Department: Business

Biovail and Acadia Pharmaceuticals are joining to commercialize pimavanserin, a drug developed by Acadia to treat psychosis caused by Parkinson's disease. It is currently in Phase III clinical trials. Biovail will make a $30 million up-front payment plus milestone payments for commercial achievements. Acadia could get up to $395 million. Separately, Biovail will acquire U.S. rights to GlaxoSmithKline's antidepressant Wellbutrin XL for $510 million. The drug, now off patent, was developed by Biovail.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment